Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 4 1Phase 1/2 1

Status

Terminated 3Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 13Genitourinary 11Other hematologic neoplasm 4Myeloid 3Lymphoid 3Gastrointestinal 3Gynecologic 2Tumor-Agnostic 1Plasma cell 1Other neoplasm 1NET 1Endocrine 1Breast 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Melanoma 1Lymphoma 1Hematologic Neoplasms 1HTLV-I Infections 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 296Cytarabine 261fludarabine phosphate 218Rituximab 195fludarabine 182Methotrexate 152Whole-Body Irradiation 140Mycophenolic Acid 124Azacitidine 122Tacrolimus 116Busulfan 110Filgrastim 104Granulocyte Colony-Stimulating Factor 98Etoposide 91Peripheral Blood Stem Cell Transplantation 90Dexamethasone 89Vincristine 88Melphalan 80Cyclosporine 74Lenalidomide 73Daunorubicin 70Decitabine 69Clofarabine 69Antilymphocyte Serum 67Calcium Dobesilate 61venetoclax 60Doxorubicin 58Imatinib Mesylate 57Alemtuzumab 56ibrutinib 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Interferon alpha-2 × Other hematologic neoplasm × Clear all
NCT04379518 2026-01-13

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Roswell Park Cancer Institute

Phase 1/2 Terminated
4 enrolled 30 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT03547154 2019-08-12

C98026

Merck Sharp & Dohme LLC

Phase 2/3 Terminated
344 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00854581 2018-04-17

Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

University of Miami

Phase 4 Terminated
13 enrolled 15 charts
LymphoidOther hematologic neoplasmOther neoplasm

Lymphoma, Precancerous Conditions, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02829775 2017-01-09

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Hoffmann-La Roche

Phase 2/3 Completed
9 enrolled 7 charts
DermatologicGenitourinaryMyeloidOther hematologic neoplasm

Carcinoma, Renal Cell, Melanoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡